SCHEMBL3005352

SCHEMBL3005352

COc1ccc(Br)cc1S(=O)(=O)C1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
P2RX7 Q99572 1/20 0.36
DRD2 P14416 5/20 0.36
DRD4 P21917 5/20 0.36
DRD3 P35462 5/20 0.36
ERBB2 P04626 3/20 0.35
EPHA2 P29317 3/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
SOS1 Q07889 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003005 0.94 GAA (0.37) GAAMAPTTP53DRD2DRD4
SCHEMBL3019234 0.93 ERBB2 (0.40) SLC6A4GAAMAPTDRD2DRD4
SCHEMBL3011794 0.93 MAPT (0.39) MAPTTP53ALDH1A1LMNAAR
SCHEMBL3009617 0.93 GAA (0.36) GAAMAPTTP53DRD2DRD4
SCHEMBL3015537 0.91 CCR3 (0.41) GAAMAPTTP53P2RX7ALDH1A1
SCHEMBL15671681 0.91 MAPT (0.38) GAAMAPTTP53DRD2DRD4
SCHEMBL3013140 0.90 DRD2 (0.39) GAAMAPTTP53DRD2DRD4
SCHEMBL3013312 0.89 GAA (0.39) GAAMAPTDRD2DRD4DRD3
SCHEMBL3014015 0.89 MAPT (0.38) GAAMAPTTP53P2RX7DRD2
SCHEMBL3009049 0.89 SOS1 (0.37) SLC6A4GAAMAPTSOS1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SLC6A4 731/4885GAA 110/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.